Mesoblast Financial Statements
Mesoblast Financial Overview
Mesoblast's market cap is currently ―. The company's EPS TTM is $-0.71; its P/E ratio is -3.46; Mesoblast is scheduled to report earnings on August 30, 2022, and the estimated EPS forecast is $-0.10. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 2.01M | $ 2.38M | $ 3.59M | $ 2.00M | $ 1.91M |
| Gross Profit | $ ― | $ ― | $ ― | $ ― | $ ― |
| EBIT | $ -17.05M | $ -21.96M | $ -19.05M | $ -18.06M | $ -22.66M |
| EBITDA | $ -17.05M | $ -21.96M | $ -19.05M | $ -18.06M | $ -22.66M |
| Net Income Common Stockholders | $ -21.30M | $ -25.95M | $ -22.64M | $ -22.06M | $ -26.52M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 76.31M | $ 77.07M | $ 94.41M | $ 107.70M | $ 115.96M |
| Total Assets | $ 681.69M | $ 704.44M | $ 721.82M | $ 744.72M | $ 766.13M |
| Total Debt | $ 54.28M | $ 58.22M | $ 88.09M | $ 99.72M | $ 118.66M |
| Net Debt | $ -22.03M | $ -18.84M | $ -6.33M | $ -7.98M | $ 2.70M |
| Total Liabilities | $ 164.56M | $ 168.93M | $ 162.07M | $ 163.32M | $ 165.19M |
| Stockholders Equity | $ 517.13M | $ 518.73M | $ 535.51M | $ 538.51M | $ 559.75M |
| Cash Flow | |||||
| Free Cash Flow | $ -15.53M | $ -16.84M | $ -19.70M | $ -25.07M | $ -25.41M |
| Operating Cash Flow | $ ― | $ ― | $ ― | $ -20.73M | $ -28.59M |
| Investing Cash Flow | $ -56.00K | $ -30.00K | $ -99.00K | $ -223.00K | $ -936.00K |
| Financing Cash Flow | $ -2.57M | $ -4.34M | $ -743.00K | $ 3.69M | $ 106.36M |